Literature DB >> 23503793

[UroLift®: an operative non-ablative procedure for treatment of benign prostatic syndrome].

R Berges1, K D Sievert, C Gratzke, U Wetterauer.   

Abstract

The implantation of a tissue retractor (UroLift®, Neotract, Pleasanton, CA) allows for the first time as a non-ablative operative technique, moderate deobstruction without removal or destruction of prostate tissue. The achievable treatment results are at least comparable to drug therapy with respect to alleviation of suffering and symptoms (primary treatment aim) and superior with respect deobstruction. The advantage of this method compared to all other conservative and operative therapy procedures is preservation of sexual function. An evaluation of this method is currently being carried out and compared to TURP in prospective, randomized studies (BPH6 study) and the results are expected in 2015.

Entities:  

Mesh:

Year:  2013        PMID: 23503793     DOI: 10.1007/s00120-012-3090-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  6 in total

1.  UroLift system for relief of prostate obstruction under local anesthesia.

Authors:  Jack Barkin; Jonathan Giddens; Peter Incze; Richard Casey; Stephen Richardson; Steven Gange
Journal:  Can J Urol       Date:  2012-04       Impact factor: 1.344

2.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

3.  Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Peter T Chin; Damien M Bolton; Greg Jack; Prem Rashid; Jeffrey Thavaseelan; R James Yu; Claus G Roehrborn; Henry H Woo
Journal:  Urology       Date:  2012-01       Impact factor: 2.649

4.  Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Authors:  Henry H Woo; Peter T Chin; Thomas A McNicholas; Harcharan S Gill; Mark K Plante; Reginald C Bruskewitz; Claus G Roehrborn
Journal:  BJU Int       Date:  2011-05-06       Impact factor: 5.588

5.  Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Henry H Woo; Damien M Bolton; Eric Laborde; Greg Jack; Peter T Chin; Prem Rashid; Jeffrey Thavaseelan; Kevin T McVary
Journal:  J Sex Med       Date:  2011-12-16       Impact factor: 3.802

6.  [New treatment strategies for male lower urinary tract symptoms].

Authors:  L F Arenas da Silva; M Schönthaler; F Cruz; C Gratzke; J Zumbe; A Stenzl; B Amend; K-D Sievert
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

  6 in total
  2 in total

1.  Ahead of the curve.

Authors:  David B Nash
Journal:  Popul Health Manag       Date:  2013       Impact factor: 2.459

2.  Effect of an employer-sponsored health and wellness program on medical cost and utilization.

Authors:  Hangsheng Liu; Katherine M Harris; Sarah Weinberger; Seth Serxner; Soeren Mattke; Ellen Exum
Journal:  Popul Health Manag       Date:  2012-07-23       Impact factor: 2.459

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.